 Edward Ashwood
Concepts (362)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prenatal Diagnosis | 14 | 2021 | 163 | 1.420 |
Why?
| | Amniotic Fluid | 16 | 2006 | 64 | 1.160 |
Why?
| | Antigens, Fungal | 4 | 2011 | 23 | 1.010 |
Why?
| | Histoplasma | 3 | 2009 | 12 | 0.920 |
Why?
| | Immunoenzyme Techniques | 4 | 2009 | 192 | 0.900 |
Why?
| | Fetal Organ Maturity | 14 | 2004 | 26 | 0.740 |
Why?
| | Histoplasmosis | 3 | 2011 | 14 | 0.730 |
Why?
| | Laboratories | 6 | 2020 | 95 | 0.700 |
Why?
| | Down Syndrome | 9 | 2021 | 335 | 0.610 |
Why?
| | Trisomy | 4 | 2020 | 68 | 0.600 |
Why?
| | Pathology, Clinical | 7 | 2014 | 32 | 0.560 |
Why?
| | Chemistry, Clinical | 6 | 2014 | 11 | 0.560 |
Why?
| | Bilirubin | 3 | 2006 | 88 | 0.540 |
Why?
| | Aspartate Aminotransferases | 1 | 2015 | 85 | 0.490 |
Why?
| | Alanine Transaminase | 1 | 2015 | 141 | 0.480 |
Why?
| | Fetal Diseases | 2 | 2013 | 146 | 0.460 |
Why?
| | Clinical Laboratory Techniques | 5 | 2013 | 86 | 0.460 |
Why?
| | DNA | 4 | 2020 | 1350 | 0.460 |
Why?
| | Pathology | 2 | 2010 | 20 | 0.440 |
Why?
| | Lung | 14 | 2004 | 3521 | 0.440 |
Why?
| | Chromosome Disorders | 1 | 2013 | 35 | 0.440 |
Why?
| | alpha 1-Antitrypsin Deficiency | 5 | 2013 | 70 | 0.410 |
Why?
| | Liver Diseases | 1 | 2015 | 254 | 0.410 |
Why?
| | Pregnancy | 28 | 2021 | 5499 | 0.400 |
Why?
| | alpha-Fetoproteins | 6 | 2013 | 31 | 0.380 |
Why?
| | Phosphatidylcholines | 12 | 2001 | 132 | 0.380 |
Why?
| | Medical Laboratory Personnel | 1 | 2010 | 7 | 0.360 |
Why?
| | Serpins | 1 | 2010 | 24 | 0.350 |
Why?
| | Antibodies, Fungal | 1 | 2009 | 9 | 0.340 |
Why?
| | Fluorescence Polarization | 10 | 1994 | 35 | 0.340 |
Why?
| | alpha 1-Antitrypsin | 4 | 2013 | 102 | 0.330 |
Why?
| | Sphingomyelins | 11 | 2001 | 26 | 0.330 |
Why?
| | Delivery of Health Care | 2 | 2015 | 828 | 0.330 |
Why?
| | Antigens, Neoplasm | 1 | 2010 | 222 | 0.310 |
Why?
| | Pancreatic Function Tests | 1 | 2008 | 3 | 0.310 |
Why?
| | Pancreatic Elastase | 1 | 2008 | 55 | 0.310 |
Why?
| | Neural Tube Defects | 3 | 2021 | 59 | 0.280 |
Why?
| | Chloroform | 1 | 2006 | 4 | 0.280 |
Why?
| | Pancreas | 1 | 2008 | 276 | 0.260 |
Why?
| | Feces | 1 | 2008 | 372 | 0.260 |
Why?
| | Humans | 76 | 2024 | 114043 | 0.250 |
Why?
| | Biomarkers, Tumor | 1 | 2010 | 1032 | 0.230 |
Why?
| | Phosphatidylglycerols | 6 | 2001 | 20 | 0.220 |
Why?
| | Renin | 1 | 2003 | 31 | 0.220 |
Why?
| | Pulmonary Surfactants | 3 | 2004 | 99 | 0.210 |
Why?
| | Reagent Kits, Diagnostic | 5 | 2015 | 42 | 0.210 |
Why?
| | Rabbits | 3 | 2009 | 733 | 0.210 |
Why?
| | Specimen Handling | 5 | 2001 | 153 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 787 | 0.200 |
Why?
| | Creatinine | 4 | 2013 | 424 | 0.200 |
Why?
| | Internship and Residency | 4 | 2014 | 920 | 0.190 |
Why?
| | Reference Values | 6 | 2013 | 739 | 0.190 |
Why?
| | Quality Control | 5 | 2008 | 143 | 0.180 |
Why?
| | Reproducibility of Results | 13 | 2015 | 2764 | 0.170 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2020 | 26 | 0.170 |
Why?
| | Phospholipids | 4 | 2001 | 194 | 0.160 |
Why?
| | Female | 35 | 2021 | 59325 | 0.160 |
Why?
| | Vaccines | 1 | 2024 | 375 | 0.160 |
Why?
| | Blood Specimen Collection | 4 | 2003 | 31 | 0.150 |
Why?
| | Phenotype | 4 | 2013 | 2784 | 0.150 |
Why?
| | Referral and Consultation | 2 | 2014 | 632 | 0.150 |
Why?
| | Laboratories, Hospital | 3 | 2013 | 14 | 0.150 |
Why?
| | Fluorescent Dyes | 6 | 1993 | 298 | 0.140 |
Why?
| | Clinical Laboratory Information Systems | 3 | 1992 | 5 | 0.140 |
Why?
| | Amniocentesis | 5 | 2013 | 21 | 0.140 |
Why?
| | Lead | 1 | 1997 | 43 | 0.140 |
Why?
| | Capillaries | 1 | 1997 | 90 | 0.140 |
Why?
| | Utah | 3 | 2014 | 59 | 0.140 |
Why?
| | Hepacivirus | 3 | 2005 | 228 | 0.140 |
Why?
| | Photosensitivity Disorders | 1 | 1996 | 7 | 0.130 |
Why?
| | Vitamin B 12 | 1 | 1997 | 115 | 0.130 |
Why?
| | Porphyrins | 1 | 1996 | 16 | 0.130 |
Why?
| | Cryopreservation | 1 | 1997 | 92 | 0.130 |
Why?
| | United States | 13 | 2021 | 12137 | 0.130 |
Why?
| | Folic Acid | 1 | 1997 | 161 | 0.130 |
Why?
| | Altitude | 1 | 2000 | 435 | 0.130 |
Why?
| | Clinical Laboratory Services | 1 | 2015 | 7 | 0.130 |
Why?
| | Blood Chemical Analysis | 2 | 2008 | 90 | 0.130 |
Why?
| | Maternal Serum Screening Tests | 1 | 2015 | 3 | 0.120 |
Why?
| | Aneuploidy | 1 | 2015 | 84 | 0.120 |
Why?
| | Infant, Newborn | 10 | 2008 | 5038 | 0.120 |
Why?
| | Curriculum | 2 | 2006 | 813 | 0.120 |
Why?
| | Hepatitis, Viral, Human | 2 | 2007 | 25 | 0.110 |
Why?
| | Blood Preservation | 1 | 1997 | 231 | 0.110 |
Why?
| | Abortion, Induced | 1 | 2015 | 71 | 0.110 |
Why?
| | Legislation, Medical | 1 | 2013 | 10 | 0.110 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 1993 | 8 | 0.110 |
Why?
| | Evaluation Studies as Topic | 7 | 2000 | 167 | 0.110 |
Why?
| | Government Regulation | 1 | 2013 | 46 | 0.100 |
Why?
| | Isoquinolines | 1 | 1993 | 36 | 0.100 |
Why?
| | Genetic Testing | 2 | 2015 | 381 | 0.100 |
Why?
| | Pregnancy Trimester, Second | 2 | 2021 | 66 | 0.100 |
Why?
| | Sensitivity and Specificity | 7 | 2013 | 1690 | 0.100 |
Why?
| | Kidney Function Tests | 1 | 2013 | 140 | 0.100 |
Why?
| | Medical Informatics | 1 | 1993 | 89 | 0.100 |
Why?
| | Neuromuscular Junction | 1 | 1993 | 53 | 0.100 |
Why?
| | Arsenic | 1 | 1992 | 37 | 0.100 |
Why?
| | Mass Spectrometry | 2 | 2011 | 622 | 0.100 |
Why?
| | Embryonic and Fetal Development | 1 | 1992 | 94 | 0.100 |
Why?
| | Chlorine | 1 | 1992 | 62 | 0.100 |
Why?
| | Software Validation | 1 | 1992 | 7 | 0.100 |
Why?
| | Chlorides | 1 | 1992 | 127 | 0.100 |
Why?
| | Observer Variation | 3 | 2009 | 298 | 0.100 |
Why?
| | RNA, Viral | 4 | 2005 | 565 | 0.100 |
Why?
| | Adult | 15 | 2015 | 30375 | 0.100 |
Why?
| | Glomerular Filtration Rate | 2 | 2013 | 605 | 0.100 |
Why?
| | Immunoglobulin G | 2 | 2024 | 766 | 0.090 |
Why?
| | Proteinuria | 1 | 2011 | 77 | 0.090 |
Why?
| | Pregnancy Complications | 2 | 1993 | 430 | 0.090 |
Why?
| | Inclusion Bodies | 2 | 2001 | 24 | 0.090 |
Why?
| | Consultants | 1 | 2011 | 12 | 0.090 |
Why?
| | Hospitals | 1 | 2015 | 581 | 0.090 |
Why?
| | Fluorescence Polarization Immunoassay | 1 | 1990 | 2 | 0.090 |
Why?
| | Mass Screening | 2 | 2015 | 979 | 0.090 |
Why?
| | Materials Testing | 1 | 1992 | 337 | 0.090 |
Why?
| | Prenatal Care | 1 | 1992 | 250 | 0.090 |
Why?
| | History, 21st Century | 1 | 2010 | 160 | 0.090 |
Why?
| | Chromatography, Liquid | 1 | 2011 | 345 | 0.080 |
Why?
| | Inhibins | 2 | 2013 | 45 | 0.080 |
Why?
| | False Positive Reactions | 2 | 2007 | 109 | 0.080 |
Why?
| | Fetal Monitoring | 1 | 1989 | 16 | 0.080 |
Why?
| | Pathology, Surgical | 1 | 2009 | 6 | 0.080 |
Why?
| | Cross Reactions | 2 | 2007 | 118 | 0.080 |
Why?
| | Water-Electrolyte Balance | 1 | 1988 | 26 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2011 | 246 | 0.080 |
Why?
| | Nickel | 1 | 1988 | 50 | 0.080 |
Why?
| | Ion Channels | 1 | 1988 | 121 | 0.080 |
Why?
| | Pregnancy Trimester, First | 2 | 2021 | 125 | 0.070 |
Why?
| | Oxygen | 1 | 1992 | 851 | 0.070 |
Why?
| | Kidney Tubules | 1 | 1988 | 107 | 0.070 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 486 | 0.070 |
Why?
| | Gestational Age | 5 | 2013 | 761 | 0.070 |
Why?
| | Respiratory Distress Syndrome, Newborn | 3 | 2004 | 101 | 0.070 |
Why?
| | Child | 8 | 2013 | 18400 | 0.070 |
Why?
| | Clinical Chemistry Tests | 1 | 2006 | 9 | 0.070 |
Why?
| | Reference Standards | 2 | 2004 | 159 | 0.070 |
Why?
| | Hepatitis, Autoimmune | 1 | 2007 | 27 | 0.070 |
Why?
| | Pediatrics | 2 | 2006 | 982 | 0.070 |
Why?
| | Animals | 9 | 2009 | 31565 | 0.070 |
Why?
| | Antibodies | 1 | 2008 | 365 | 0.070 |
Why?
| | Solvents | 1 | 2006 | 104 | 0.070 |
Why?
| | DNA, Viral | 2 | 2005 | 349 | 0.070 |
Why?
| | Child, Preschool | 5 | 2013 | 9114 | 0.060 |
Why?
| | Conflict of Interest | 1 | 2007 | 119 | 0.060 |
Why?
| | Actins | 2 | 2007 | 376 | 0.060 |
Why?
| | Proteins | 1 | 2011 | 906 | 0.060 |
Why?
| | Infant | 4 | 2013 | 7943 | 0.060 |
Why?
| | Data Collection | 2 | 2005 | 618 | 0.060 |
Why?
| | Hepatitis B virus | 1 | 2005 | 25 | 0.060 |
Why?
| | Algorithms | 2 | 2013 | 1469 | 0.060 |
Why?
| | Middle Aged | 7 | 2015 | 26605 | 0.060 |
Why?
| | Teaching | 1 | 2006 | 209 | 0.060 |
Why?
| | Hematologic Tests | 1 | 2004 | 22 | 0.060 |
Why?
| | Monte Carlo Method | 2 | 2015 | 136 | 0.060 |
Why?
| | Hyperbilirubinemia | 1 | 2003 | 14 | 0.060 |
Why?
| | Blood Gas Analysis | 1 | 1983 | 70 | 0.050 |
Why?
| | Spectrophotometry | 1 | 2003 | 47 | 0.050 |
Why?
| | Mathematics | 1 | 1983 | 107 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2002 | 924 | 0.050 |
Why?
| | Central Nervous System Diseases | 1 | 2003 | 60 | 0.050 |
Why?
| | Aged | 5 | 2013 | 18969 | 0.050 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 544 | 0.050 |
Why?
| | Postoperative Complications | 1 | 1993 | 2122 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1257 | 0.050 |
Why?
| | Young Adult | 3 | 2013 | 10444 | 0.050 |
Why?
| | Risk | 3 | 2007 | 810 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2001 | 13 | 0.050 |
Why?
| | Sarcoidosis | 1 | 2003 | 133 | 0.050 |
Why?
| | Adolescent | 4 | 2013 | 17800 | 0.050 |
Why?
| | Prospective Studies | 5 | 1993 | 6195 | 0.050 |
Why?
| | HIV Antibodies | 1 | 2001 | 49 | 0.050 |
Why?
| | Acute Disease | 2 | 2007 | 907 | 0.050 |
Why?
| | Isoelectric Focusing | 2 | 2013 | 33 | 0.050 |
Why?
| | Immunoassay | 1 | 2001 | 95 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2024 | 520 | 0.040 |
Why?
| | Genotype | 4 | 2007 | 1757 | 0.040 |
Why?
| | HIV Seropositivity | 1 | 2001 | 109 | 0.040 |
Why?
| | Maternal Age | 2 | 2013 | 116 | 0.040 |
Why?
| | Trisomy 18 Syndrome | 1 | 2020 | 2 | 0.040 |
Why?
| | Trisomy 13 Syndrome | 1 | 2020 | 3 | 0.040 |
Why?
| | Estriol | 2 | 2013 | 5 | 0.040 |
Why?
| | Chorionic Gonadotropin | 2 | 2013 | 78 | 0.040 |
Why?
| | Autoantibodies | 1 | 2007 | 1347 | 0.040 |
Why?
| | Polymerase Chain Reaction | 3 | 2007 | 990 | 0.040 |
Why?
| | Health Personnel | 1 | 2024 | 569 | 0.040 |
Why?
| | Time Factors | 3 | 1997 | 6077 | 0.040 |
Why?
| | Predictive Value of Tests | 4 | 2005 | 1791 | 0.040 |
Why?
| | Hepatitis C | 1 | 2000 | 218 | 0.040 |
Why?
| | Syndrome | 1 | 1998 | 330 | 0.040 |
Why?
| | Male | 7 | 2013 | 55396 | 0.040 |
Why?
| | History, 20th Century | 1 | 1998 | 265 | 0.040 |
Why?
| | Drug Storage | 1 | 1997 | 57 | 0.040 |
Why?
| | Centrifugation | 2 | 1988 | 31 | 0.030 |
Why?
| | Hand Disinfection | 1 | 1997 | 22 | 0.030 |
Why?
| | Drug Stability | 1 | 1997 | 151 | 0.030 |
Why?
| | Congresses as Topic | 1 | 1998 | 193 | 0.030 |
Why?
| | Veins | 1 | 1997 | 55 | 0.030 |
Why?
| | Retrospective Studies | 5 | 2014 | 12521 | 0.030 |
Why?
| | Porphobilinogen | 1 | 1996 | 1 | 0.030 |
Why?
| | Uroporphyrins | 1 | 1996 | 1 | 0.030 |
Why?
| | Porphyria Cutanea Tarda | 1 | 1996 | 1 | 0.030 |
Why?
| | Coproporphyrins | 1 | 1996 | 3 | 0.030 |
Why?
| | Coronary Disease | 1 | 1998 | 348 | 0.030 |
Why?
| | Membrane Fluidity | 3 | 1990 | 10 | 0.030 |
Why?
| | Freezing | 2 | 1986 | 84 | 0.030 |
Why?
| | HIV-1 | 1 | 2001 | 768 | 0.030 |
Why?
| | Hospital Administration | 1 | 2015 | 22 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 82 | 0.030 |
Why?
| | Commerce | 1 | 2015 | 61 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2015 | 61 | 0.030 |
Why?
| | Neutrophils | 2 | 1990 | 1089 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1996 | 465 | 0.030 |
Why?
| | Health Care Reform | 1 | 2015 | 92 | 0.030 |
Why?
| | Ampyrone | 1 | 1994 | 1 | 0.030 |
Why?
| | Glycerol Kinase | 1 | 1994 | 1 | 0.030 |
Why?
| | Glycerolphosphate Dehydrogenase | 1 | 1994 | 4 | 0.030 |
Why?
| | Chromogenic Compounds | 1 | 1994 | 2 | 0.030 |
Why?
| | Phospholipase D | 1 | 1994 | 7 | 0.030 |
Why?
| | Microchemistry | 1 | 1994 | 15 | 0.030 |
Why?
| | Professional Competence | 1 | 2014 | 81 | 0.030 |
Why?
| | Pregnancy Trimesters | 1 | 2013 | 13 | 0.030 |
Why?
| | 4-Chloro-7-nitrobenzofurazan | 1 | 1993 | 3 | 0.030 |
Why?
| | In Vitro Techniques | 3 | 1990 | 1003 | 0.030 |
Why?
| | Butyrylcholinesterase | 1 | 1993 | 1 | 0.030 |
Why?
| | Cytological Techniques | 1 | 1993 | 24 | 0.030 |
Why?
| | Cholinesterases | 1 | 1993 | 6 | 0.030 |
Why?
| | Pentoxifylline | 2 | 1990 | 21 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2000 | 1381 | 0.030 |
Why?
| | Education, Medical, Continuing | 1 | 2014 | 115 | 0.030 |
Why?
| | Vanadium | 1 | 1992 | 4 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1990 | 128 | 0.030 |
Why?
| | Abortion, Spontaneous | 1 | 2013 | 89 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 2013 | 196 | 0.030 |
Why?
| | Albumins | 1 | 1992 | 89 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2013 | 172 | 0.020 |
Why?
| | Cell Separation | 1 | 1993 | 290 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 437 | 0.020 |
Why?
| | Systems Analysis | 1 | 1992 | 21 | 0.020 |
Why?
| | Health Care Costs | 1 | 2015 | 381 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2013 | 4595 | 0.020 |
Why?
| | Catheterization, Swan-Ganz | 1 | 1990 | 8 | 0.020 |
Why?
| | Virulence Factors, Bordetella | 1 | 1990 | 19 | 0.020 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 1990 | 15 | 0.020 |
Why?
| | Pertussis Toxin | 1 | 1990 | 24 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1994 | 917 | 0.020 |
Why?
| | Endothelium, Lymphatic | 1 | 1990 | 12 | 0.020 |
Why?
| | Erythrocyte Membrane | 1 | 1990 | 50 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2011 | 167 | 0.020 |
Why?
| | Security Measures | 1 | 1990 | 6 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 8614 | 0.020 |
Why?
| | Theobromine | 1 | 1989 | 2 | 0.020 |
Why?
| | Sodium | 1 | 1990 | 184 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 1991 | 82 | 0.020 |
Why?
| | Hemolysis | 1 | 1990 | 143 | 0.020 |
Why?
| | Information Systems | 1 | 1990 | 61 | 0.020 |
Why?
| | Calibration | 1 | 1990 | 125 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1990 | 70 | 0.020 |
Why?
| | Biomarkers | 2 | 2013 | 3397 | 0.020 |
Why?
| | Hypotonic Solutions | 1 | 1988 | 1 | 0.020 |
Why?
| | Blood Protein Electrophoresis | 1 | 2008 | 7 | 0.020 |
Why?
| | Lymphocytes | 1 | 1990 | 327 | 0.020 |
Why?
| | Electrophoresis, Capillary | 1 | 2008 | 21 | 0.020 |
Why?
| | Particle Size | 1 | 1990 | 317 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 1988 | 34 | 0.020 |
Why?
| | Goldfish | 1 | 1988 | 29 | 0.020 |
Why?
| | Erythrocytes | 1 | 1993 | 568 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 1988 | 43 | 0.020 |
Why?
| | Cell Adhesion | 1 | 1990 | 426 | 0.020 |
Why?
| | Sodium Channels | 1 | 1988 | 61 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 1988 | 77 | 0.020 |
Why?
| | Potassium Channels | 1 | 1988 | 121 | 0.020 |
Why?
| | Proteome | 1 | 2011 | 337 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 63 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 665 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2008 | 337 | 0.020 |
Why?
| | Pregnancy, High-Risk | 1 | 1987 | 12 | 0.020 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 1987 | 10 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 1989 | 337 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2007 | 48 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 137 | 0.020 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 1991 | 505 | 0.020 |
Why?
| | Fetus | 1 | 1990 | 698 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 476 | 0.020 |
Why?
| | Chromatography, Thin Layer | 1 | 1986 | 22 | 0.020 |
Why?
| | Muscle, Smooth | 1 | 2007 | 142 | 0.020 |
Why?
| | Medical Staff, Hospital | 1 | 2006 | 74 | 0.020 |
Why?
| | Societies, Medical | 1 | 2009 | 655 | 0.020 |
Why?
| | Solutions | 1 | 1986 | 144 | 0.020 |
Why?
| | Amnion | 1 | 1985 | 24 | 0.020 |
Why?
| | Respiration Disorders | 1 | 1986 | 68 | 0.020 |
Why?
| | Cattle | 2 | 2001 | 918 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1990 | 1128 | 0.020 |
Why?
| | Ultracentrifugation | 1 | 2005 | 46 | 0.010 |
Why?
| | Bacteriological Techniques | 1 | 2005 | 63 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 2013 | 6306 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 789 | 0.010 |
Why?
| | Hepatitis B | 1 | 2005 | 51 | 0.010 |
Why?
| | Child Health Services | 1 | 2006 | 175 | 0.010 |
Why?
| | Dimerization | 1 | 2004 | 176 | 0.010 |
Why?
| | Plasma | 1 | 2005 | 181 | 0.010 |
Why?
| | Temperature | 1 | 1986 | 564 | 0.010 |
Why?
| | Neonatal Screening | 1 | 2004 | 151 | 0.010 |
Why?
| | Body Temperature | 1 | 1983 | 208 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 882 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1983 | 507 | 0.010 |
Why?
| | Blood Glucose | 1 | 1990 | 1827 | 0.010 |
Why?
| | Goats | 1 | 2001 | 26 | 0.010 |
Why?
| | Serum Albumin, Bovine | 1 | 2001 | 60 | 0.010 |
Why?
| | Antibody Specificity | 1 | 2001 | 175 | 0.010 |
Why?
| | Microspheres | 1 | 2001 | 123 | 0.010 |
Why?
| | Likelihood Functions | 1 | 2001 | 126 | 0.010 |
Why?
| | Antigens, Viral | 1 | 2001 | 176 | 0.010 |
Why?
| | Butanols | 2 | 1990 | 8 | 0.010 |
Why?
| | Structure-Activity Relationship | 2 | 1990 | 499 | 0.010 |
Why?
| | Placenta | 1 | 1985 | 628 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2090 | 0.010 |
Why?
| | Research Design | 1 | 2004 | 919 | 0.010 |
Why?
| | Signal Transduction | 1 | 2011 | 4501 | 0.010 |
Why?
| | Sheep | 1 | 2001 | 761 | 0.010 |
Why?
| | Blotting, Western | 1 | 2001 | 1143 | 0.010 |
Why?
| | Cell Movement | 2 | 1990 | 863 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1991 | 3254 | 0.010 |
Why?
| | Chromatography | 1 | 1993 | 23 | 0.010 |
Why?
| | Cell Size | 1 | 1993 | 79 | 0.010 |
Why?
| | Horses | 1 | 1993 | 96 | 0.010 |
Why?
| | Cats | 1 | 1993 | 193 | 0.010 |
Why?
| | Dogs | 1 | 1993 | 331 | 0.010 |
Why?
| | Species Specificity | 1 | 1993 | 541 | 0.010 |
Why?
| | Fee Schedules | 1 | 1991 | 3 | 0.010 |
Why?
| | Glycols | 1 | 1990 | 4 | 0.010 |
Why?
| | Melitten | 1 | 1990 | 3 | 0.010 |
Why?
| | Elapid Venoms | 1 | 1990 | 14 | 0.010 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 1990 | 31 | 0.010 |
Why?
| | Germ-Free Life | 1 | 1990 | 28 | 0.010 |
Why?
| | Mice | 2 | 2001 | 14841 | 0.010 |
Why?
| | Alcohols | 1 | 1990 | 28 | 0.010 |
Why?
| | Appointments and Schedules | 1 | 1991 | 70 | 0.010 |
Why?
| | 1-Butanol | 1 | 1990 | 2 | 0.010 |
Why?
| | Receptors, Leukocyte-Adhesion | 1 | 1990 | 5 | 0.010 |
Why?
| | Plant Proteins | 1 | 1990 | 81 | 0.010 |
Why?
| | Macrophage-1 Antigen | 1 | 1990 | 25 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1990 | 242 | 0.010 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 1990 | 75 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1990 | 79 | 0.010 |
Why?
| | Sodium Chloride | 1 | 1990 | 133 | 0.010 |
Why?
| | Receptors, Concanavalin A | 1 | 1989 | 2 | 0.010 |
Why?
| | Lipid Bilayers | 1 | 1990 | 94 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1990 | 396 | 0.010 |
Why?
| | Benzimidazoles | 1 | 1990 | 137 | 0.010 |
Why?
| | Confidentiality | 1 | 1990 | 67 | 0.010 |
Why?
| | Catheterization, Peripheral | 1 | 1990 | 100 | 0.010 |
Why?
| | Heparin | 1 | 1990 | 225 | 0.010 |
Why?
| | Regression Analysis | 1 | 1991 | 945 | 0.000 |
Why?
| | Antigens, CD | 1 | 1990 | 440 | 0.000 |
Why?
| | Receptors, Cell Surface | 1 | 1989 | 350 | 0.000 |
Why?
| | Rh Isoimmunization | 1 | 1985 | 3 | 0.000 |
Why?
| | Sex Chromosome Aberrations | 1 | 1985 | 51 | 0.000 |
Why?
| | B-Lymphocytes | 1 | 1990 | 762 | 0.000 |
Why?
| | Models, Biological | 1 | 1990 | 1611 | 0.000 |
Why?
| | Ultrasonography | 1 | 1985 | 635 | 0.000 |
Why?
| | Mice, Inbred C57BL | 1 | 1990 | 4680 | 0.000 |
Why?
| | Hemorrhage | 1 | 1985 | 600 | 0.000 |
Why?
|
|
Ashwood's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|